Expression of LAPTM4B-35: A novel marker of progression, invasiveness and poor prognosis of extrahepatic cholangiocarcinoma

Cancer Letters

Volumn 264, Issue 2, 2008, Pages 209-217

  Zhou, Li ^a   He, Xiao Dong ^a   Cui, Quan Cai ^a   Zhou, Wei Xun ^a   Qu, Qiang ^a   Zhou, Rou Li ^b   Rui, Jing An ^a   Yu, Jian Chun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

Extrahepatic cholangiocarcinoma; Lysosome associated protein transmembrane 4 beta; Resection; Survival

Indexed keywords

CA 19-9 ANTIGEN; MOLECULAR MARKER; PROTEIN LAPTM4B; PROTEIN LAPTM4B 35; TUMOR MARKER;

ADULT; AGED; ARTICLE; BILE DUCT CARCINOMA; CANCER GRADING; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CELL DIFFERENTIATION; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LAPTM4B GENE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PERINEURIUM; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TUMOR GENE;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CHOLANGIOCARCINOMA; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; MALE; MEMBRANE PROTEINS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ONCOGENE PROTEINS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 42749093205     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.01.025     Document Type: Article

References (28)

1. Blom D., and Schwartz S.I. Surgical treatment and outcomes in carcinoma of the extrahepatic bile ducts: the University of Rochester experience. Arch. Surg. 136 (2001) 209-215
2. Johnson S.R., Kelly B.S., Pennington L.J., and Hanto D.W. A single center experience with extrahepatic cholangiocarcinomas. Surgery 130 (2001) 584-590
3. Stein D.E., Heron D.E., Rosato E.L., Anne P.R., and Topham A.K. Positive microscopic margins alter outcome in lymph node-negative cholangiocarcinoma when resection is combined with adjuvant radiotherapy. Am. J. Clin. Oncol. 28 (2005) 21-23
4. Hong S.M., Kim M.J., Cho H., et al. Superficial vs deep pancreatic parenchymal invasion in the extrahepatic bile duct carcinomas: a significant prognostic factor. Mod. Pathol. 18 (2005) 969-975
5. Hong S.M., Cho H., Lee O.J., and Ro J.Y. The number of metastatic lymph nodes in extrahepatic bile duct carcinoma as a prognostic factor. Am. J. Surg. Pathol. 29 (2005) 1177-1183
6. Enjoji M., Nakashima M., Nishi H., et al. The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract. J. Hepatol. 36 (2002) 786-792
7. Ito Y., Miyoshi E., Takeda T., et al. ets-1 expression in extrahepatic bile duct carcinoma and cholangiocellular carcinoma. Oncology 58 (2000) 248-252
8. Ito Y., Takeda T., Sasaki Y., et al. Expression of p57/Kip2 protein in extrahepatic bile duct carcinoma and intrahepatic cholangiocellular carcinoma. Liver 22 (2002) 145-149
9. Suzuoki M., Hida Y., Miyamoto M., et al. RCAS1 expression as a prognostic factor after curative surgery for extrahepatic bile duct carcinoma. Ann. Surg. Oncol. 9 (2002) 388-393
10. Murakami S., Miyamoto M., Hida Y., et al. Caveolin-I overexpression is a favourable prognostic factor for patients with extrahepatic bile duct carcinoma. Br. J. Cancer 88 (2003) 1234-1238
11. Tamada S., Shibahara H., Higashi M., et al. MUC4 is a novel prognostic factor of extrahepatic bile duct carcinoma. Clin. Cancer Res. 12 (2006) 4257-4264
12. Liu J., Zhou R., Zhang N., Rui J., and Jin C. Biological function of a novel gene overexpressed in human hepatocellular carcinoma. Chin. Med. J. 113 (2000) 881-885
13. Shao G.Z., Zhou R.L., Zhang Q.Y., et al. Molecular cloning and characterization of LAPTM4B, a novel gene upregulated in hepatocellular carcinoma. Oncogene 22 (2003) 5060-5069
14. Liu X.R., Zhou R.L., Zhang Q.Y., et al. Structure analysis and expressions of a novel tetratransmembrane protein, lysosoma-associated protein transmembrane 4 beta associated with hepatocellular carcinoma. World J. Gastroenterol. 10 (2004) 1555-1559
15. Peng C., Zhou R.L., Shao G.Z., et al. Expression of lysosome-associated protein transmembrane 4B-35 in cancer and its correlation with the differentiation status of hepatocellular carcinoma. World J. Gastroenterol. 11 (2005) 2704-2708
16. Kasper G., Vogel A., Klaman I., et al. The human LAPTM4b transcript is upregulated in various types of solid tumours and seems to play a dual functional role during tumour progression. Cancer Lett. 224 (2005) 93-103
17. Morris D.G., Musat M., Czirjak S., et al. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur. J. Endocrinol. 153 (2005) 143-151
18. Zhou L., He X.D., Chen J., et al. Overexpression of LAPTM4B-35 closely correlated with clinicopathological features and post-resectional survival of gallbladder carcinoma. Eur. J. Cancer 43 (2007) 809-815
19. In: Greene F.L., Page D.L., Fleming I.D., et al. (Eds). American Joint Committee on Cancer Staging Manual. sixth ed. (2002), Springer-Verlag, New York 145-150
20. Deng L.J., Zhang Q.Y., Liu B., and Zhou R.L. Relationship between LAPTM4B gene polymorphism and susceptibility of lung cancer. Beijing Da Xue Xue Bao 37 (2005) 302-305
21. Liu Y., Zhang Q.Y., Qian N., and Zhou R.L. Relationship between LAPTM4B gene polymorphism and susceptibility of gastric cancer. Ann. Oncol. 18 (2007) 311-316
22. He J., Shao G., and Zhou R. Effects of the novel gene, LAPTM4B, highly expression in hepatocellular carcinoma on cell proliferation and tumorigenesis of NIH3T3 cells. Beijing Da Xue Xue Bao 35 (2003) 348-352
23. Malhi H., and Gores G.J. Cholangiocarcinoma: modern advances in understanding a deadly old disease. J. Hepatol. 45 (2006) 856-867
24. Hui A.M., Cui X., Makuuchi M., Li X., Shi Y.Z., and Takayama T. Decreased p27(Kip1) expression and cyclin D1 overexpression, alone and in combination, influence recurrence and survival of patients with respectable extrahepatic bile duct carcinoma. Hepatology 30 (1999) 1167-1173
25. Ohtsuka M., Ito H., Kimura F., et al. Results of surgical treatment for intrahepatic cholangiocarcinoma and clinicopathological factors influencing survival. Br. J. Surg. 89 (2002) 1525-1531
26. Abdel Wahab M., Fathy O., Elghwalby N., et al. Resectability and prognostic factors after resection of hilar cholangiocarcinoma. Hepatogastroenterology 53 (2006) 5-10
27. Miwa S., Miyagawa S., Kobayashi A., et al. Predictive factors for intrahepatic cholangiocarcinoma recurrence in the liver following surgery. J. Gastroenterol. 41 (2006) 893-900
28. Berg E.L., Robinson M.K., Mansson O., Butcher E.C., and Magnani J.L. A carbohydrate domain common to both sialyl Le(a) and sialyl Le(X) is recognized by the endothelial cell leukocyte adhesion molecule ELAM-1. J. Biol. Chem. 266 (1991) 14869-14872